for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Constellation Pharmaceuticals Inc

CNST.OQ

Latest Trade

12.45USD

Change

0.67(+5.69%)

Volume

75,839

Today's Range

11.22

 - 

12.56

52 Week Range

4.01

 - 

14.04

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Constellation Pharmaceuticals Announces $65 Million Private Placement With New And Existing Investors

Oct 1 (Reuters) - Constellation Pharmaceuticals Inc <CNST.O>::CONSTELLATION PHARMACEUTICALS ANNOUNCES $65 MILLION PRIVATE PLACEMENT WITH NEW AND EXISTING INVESTORS.CONSTELLATION PHARMACEUTICALS INC - COMPANY IS SELLING 7.6 MILLION SHARES OF COMMON STOCK AT A PRICE OF $8.50 PER SHARE.CONSTELLATION PHARMACEUTICALS - TO USE NET PROCEEDS TO FUND RESEARCH AND DEVELOPMENT EXPENSES, TO ADVANCE CURRENT PIPELINE OF PRECLINICAL CANDIDATES.CONSTELLATION PHARMACEUTICALS INC - PRIVATE PLACEMENT IS BEING LED BY VENROCK HEALTHCARE CAPITAL PARTNERS.CONSTELLATION PHARMACEUTICALS INC - PRIVATE PLACEMENT INCLUDES BAIN CAPITAL LIFE SCIENCES AND AFFILIATES OF COLUMN GROUP.

Constellation Pharmaceuticals Q2 Loss Per Share $0.80

Aug 7 (Reuters) - Constellation Pharmaceuticals Inc <CNST.O>::CONSTELLATION PHARMACEUTICALS ANNOUNCES SECOND-QUARTER AND SIX-MONTH 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.80.Q2 EARNINGS PER SHARE ESTIMATE $-0.81 -- REFINITIV IBES DATA.PROSTAR STUDY OF CPI-1205 REMAINS ON TRACK, AND IND FOR CPI-0209 WAS FILED AND CLEARED BY FDA.EZH2 FRANCHISE CONTINUES TO ADVANCE.CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES AS OF JUNE 30, 2019, WERE $98.1 MILLION.

Constellation Pharmaceuticals Files For Mixed Shelf Of Upto $200 Mln

Aug 2 (Reuters) - Constellation Pharmaceuticals Inc <CNST.O>::CONSTELLATION PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $200 MILLION - SEC FILING.

Constellation Pharmaceuticals Q1 Loss Per Share $0.75

May 8 (Reuters) - Constellation Pharmaceuticals Inc <CNST.O>::CONSTELLATION PHARMACEUTICALS ANNOUNCES FIRST-QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.75.Q1 EARNINGS PER SHARE ESTIMATE $-0.80 -- REFINITIV IBES DATA.CONSTELLATION PHARMACEUTICALS - CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES AS OF MARCH 31, 2019, UP 1.0% COMPARED TO DEC 31, 2018, TO $115.8 MILLION.CONSTELLATION PHARMACEUTICALS - SEES CASH,CASH EQUIVALENTS, MARKETABLE SECURITIES AS OF MARCH 31, 2019, TO FUND OPERATING EXPENSES & CAPEX TO Q3 2020.

Constellation Pharmaceuticals Says Entered Into A Loan And Security Agreement

March 21 (Reuters) - Constellation Pharmaceuticals Inc <CNST.O>::CONSTELLATION PHARMACEUTICALS INC - ENTERED INTO A LOAN AND SECURITY AGREEMENT.CONSTELLATION PHARMACEUTICALS INC - TERM LOAN OF UP TO AN AGGREGATE PRINCIPAL AMOUNT OF $40.0 MILLION IS AVAILABLE TO COMPANY.CONSTELLATION PHARMACEUTICALS INC - LOAN AGREEMENT PROVIDES FOR AN INITIAL TERM LOAN ADVANCE OF $20.0 MILLION.CONSTELLATION PHARMACEUTICALS INC - TERM LOAN BEARS INTEREST AT AN ANNUAL RATE EQUAL TO GREATER OF 8.55% AND PRIME RATE OF INTEREST PLUS 2.55%..

Constellation Pharmaceuticals Announces Fourth-Quarter And Full-Year 2018 Financial Results

March 14 (Reuters) - Constellation Pharmaceuticals Inc <CNST.O>::CONSTELLATION PHARMACEUTICALS ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.77.Q4 EARNINGS PER SHARE ESTIMATE $-0.74 -- REFINITIV IBES DATA.CASH AND CASH EQUIVALENTS AS OF DECEMBER 31, 2018 DECREASED 10.8% TO $114.6 MILLION COMPARED TO SEPTEMBER 30, 2018.EXPECT THAT CASH AND CASH EQUIVALENTS WILL FUND OPERATING EXPENSES AND CAPEX REQUIREMENTS INTO Q2 OF 2020.

Constellation Pharma Inc Says Post-IPO Cash Expected To Fund Operations Into Q2 2020

Jan 7 (Reuters) - Constellation Pharmaceuticals Inc <CNST.O>::CONSTELLATION PHARMACEUTICALS INC - POST-IPO CASH EXPECTED TO FUND OPERATIONS INTO Q2 2020.

Constellation Pharmaceuticals Says Plans To Initiate Phase 1 Clinical Trial Of CPI-0209 In Mid-2019

Jan 3 (Reuters) - Constellation Pharmaceuticals Inc <CNST.O>::CONSTELLATION PHARMACEUTICALS PROVIDES UPDATE ON MANIFEST CLINICAL TRIAL OF CPI-0610 IN MYELOFIBROSIS, REVIEWS 2018 ACCOMPLISHMENTS, AND ANNOUNCES 2019 DATA DISCLOSURE PLANS FOR LEAD PROGRAMS.CONSTELLATION PHARMACEUTICALS INC - PLANS TO INITIATE A PHASE 1 CLINICAL TRIAL OF CPI-0209 IN MID-2019.CONSTELLATION PHARMACEUTICALS - AS OF DEC 10, EACH OF FIRST FOUR RUXOLITINIB-RESISTANT SECOND-LINE MF PATIENTS IN MANIFEST REMAINED ON STUDY.CONSTELLATION PHARMACEUTICALS - RESULTS SUGGEST CPI-0610 MAY BE MODIFYING UNDERLYING COURSE OF DISEASE IN THESE RUXOLITINIB-RESISTANT MF PATIENTS.

Constellation Pharma Initiates Phase 2 Portion Of Prostar Clinical Trial In Patients With Type Of Prostate Cancer

Dec 10 (Reuters) - Constellation Pharmaceuticals Inc <CNST.O>::CONSTELLATION PHARMACEUTICALS INITIATES PHASE 2 PORTION OF PROSTAR CLINICAL TRIAL IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC).CONSTELLATION PHARMACEUTICALS INC - PRELIMINARY PHASE 1B RESULTS SUGGEST CPI-1205 IS WELL-TOLERATED.CONSTELLATION PHARMACEUTICALS INC - CONTINUES TO EXPECT TO DETERMINE PROOF OF CONCEPT FOR CPI-1205 IN MID-2019..

Constellation Pharmaceuticals Reports Q3 Loss Per Share Of $0.81

Nov 8 (Reuters) - Constellation Pharmaceuticals Inc <CNST.O>::CONSTELLATION PHARMACEUTICALS ANNOUNCES THIRD-QUARTER AND NINE-MONTH 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.81.Q3 EARNINGS PER SHARE VIEW $-0.67 -- THOMSON REUTERS I/B/E/S.EXPECTS TO EVALUATE PROOF OF CONCEPT FOR CPI-1205 AND CPI-0610 PROGRAMS IN MID-2019.CONSTELLATION PHARMACEUTICALS - EXPECT CASH AS OF SEPT 30, 2018, WILL FUND PLANNED OPERATIONS INTO Q1 2020.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up